| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Janux Therapeutics, Inc.$16.4
-0.57 (-3.4%)
C 42Pipeline Score Fair Value Biotech · Commercial
Market Cap
885.49 M
EPS
-1.84
P/E Ratio
-
Value Trade
9.36 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.73 M
R&D Expenses
26.81 M
Operating CF
-12.34 M
Total Assets
1.03 B
Total Liabilities
86.69 M
Equity
941.53 M
D/E Ratio
12,345
1.54 %
Week
-6.68 %
1 Month
9.26 %
3 Month
-49.23 %
6 Month
-57.29 %
5 Year
-57.29 %
All Time
Cash Data
Cash Position
956.39 M
Monthly Burn
4.11 M
Runway
230.7 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
888.41 K
52 Week Range
12.12 - 35.34
% held by Insiders
6.1 %
% held by Institutions
96.67 %
Enterprise Value
-49.32 M
Total Shares
60.16 M
Short %
19.18 %
Float Shares
37.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Janux Therapeutics, Inc.
126Total events
2Upcoming
16Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
Event history 124
May 7, 2026
▲Trial InitiationJANX014Trial
Clinical initiation of JANX014
metastatic castration-resistant prostate cancersource ↗
May 7, 2026
▲Trial InitiationJANX013Trial
Advancement of JANX013 toward the clinic
metastatic castration-resistant prostate cancersource ↗
May 7, 2026
▲Trial InitiationJANX011Trial
Ongoing Phase 1 clinical study of JANX011 in healthy volunteers
autoimmune diseasessource ↗
Apr 28, 2026
▼Trial DiscontinuedJANX008DiscontinuedTrial
Discontinuation of JANX008 clinical development
solid tumorssource ↗
Apr 27, 2026
▼Program DiscontinuationJANX008DiscontinuedCorporate
Discontinuation of JANX008 clinical development
Apr 17, 2026
▲First Patient DosedJANX014Trial
First participant dosed in Phase 1 study of JANX014
metastatic castration-resistant prostate cancer (mCRPC)source ↗
Apr 16, 2026
Apr 1, 2026
▲Development Candidate NominationPreclinical
Development candidate nomination under Bristol Myers Squibb collaboration
solid tumorsource ↗
Feb 17, 2026
▲First Patient DosedJANX011Trial
First participant dosed in Phase 1 study of JANX011
autoimmune diseasessource ↗
Jan 22, 2026
▲Partnership / LicenseCorporate
Collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors
solid tumorssource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $438M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.7x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankJanux Therapeutics, Inc. carries a moderate pipeline score (42/100), with $1.1B risk-adjusted pipeline value, led by JANX007 in Prostate Cancer (Phase 1), across $59B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JANX014 Monoclonal antibody | Prostate Cancer | Phase 1 | NCT07545811 | 9% | $355M | RECRUITING | 43 | VERY_FAST | D (31) | Mar 1, 2029 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
JANX008 | solid tumors | Phase 1a | 2026-04-28 | durable responses were observed in select patients | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development Read More | |
JANX008 | solid tumors | Phase 1a | 2026-04-28 | durable responses were observed in select patients | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development Read More | |
JANX008 | solid tumors | Phase 1a | 2026-04-28 | durable responses were observed in select patients | Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in JANX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
JANX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
JANXJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics has reported its financial results for the first quarter of 2026. The report includes various business highlights, although specific details about financial performance or strategic initiatives are not provided in the article. The overall tone remains neutral without significant positive or negative developments.
Read more →JANXJanux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics has announced the discontinuation of its JANX008 clinical development after evaluating the Phase 1a study results. Despite some durable responses in select patients, the overall activity was not sufficient to justify further investment. The company will redirect resources to other pipeline opportunities while continuing to develop its broader TRACTr platform.
Read more →JANXJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Janux Therapeutics has initiated a Phase 1 clinical trial for JANX014, a T cell engager targeting metastatic castration-resistant prostate cancer (mCRPC). This trial marks the first patient dosing and aims to assess the safety and efficacy of the treatment. The company is building on its existing prostate cancer programs, including JANX007, which has shown promising early results.
Read more →JANXJanux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics has announced the nomination of a development candidate under its collaboration with Bristol Myers Squibb. This milestone achievement has triggered a $35 million payment. The candidate utilizes Janux's TRACTr platform to target a specific solid tumor antigen, marking a significant advancement in their immunotherapy pipeline.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in its clinical pipeline, particularly with JANX007 and JANX008. The company has formed a strategic collaboration with Bristol Myers Squibb, which is expected to provide capital and validate its platform. Janux is focused on expanding its product candidates and enhancing its clinical strategy for future growth.
Read more →JANXJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has announced the dosing of the first participant in a Phase 1 clinical study of JANX011, a bispecific targeting CD19 for autoimmune diseases. This study aims to evaluate the safety and pharmacodynamics of JANX011, which has shown promising preclinical results. The ARM platform may offer advantages over conventional therapies, with potential applications in hematologic malignancies as well.
Read more →JANX▲ +14.1%on this news
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Janux Therapeutics has entered into a collaboration and exclusive license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors. This partnership aims to leverage Janux's proprietary technology and Bristol's expertise to accelerate the delivery of new treatments. Janux will handle preclinical development, while Bristol will manage IND submission and commercialization, with potential financial benefits of up to $800 million.
Read more →JANXJanux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
Janux Therapeutics has provided an update on its ongoing Phase 1 study of JANX008, an EGFR-targeted TRACTr for various solid tumors. The study has completed its dose-escalation phase and is now moving into expansion cohorts for further evaluation. Janux plans to share more updates as the study progresses.
Read more →JANX▼ -53.3%on this news
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Janux Therapeutics announced positive interim data from its Phase 1 clinical trial of JANX007, a PSMA-directed TRACTr for mCRPC. The trial showed durable responses and a manageable safety profile, with high PSA response rates. The company is exploring further applications of JANX007 in earlier-line treatments and in combination therapies.
Read more →JANXJanux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights • Enrollment ongoing for JANX007 and JANX008 • Updates on JANX007 and JANX008 expected in the fourth quarter of 2025 &
Janux Therapeutics reported its third quarter 2025 financial results, showing ongoing enrollment in two clinical trials for its drug candidates JANX007 and JANX008. The company reported a strong cash position of $989 million, aiding its operational capabilities. Over the past year, Janux has reduced its net loss, which may reflect improved financial management. However, increased research and development costs and the challenges of upcoming clinical trials present risks to the company’s outlook.
Read more →JANX▼ -6.6%on this news
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights • R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform
Janux Therapeutics reported its financial results for Q2 2025, highlighting advancements in its TRACTr, TRACIr, and ARM pipelines, which target various cancers and autoimmune diseases. Key updates include ongoing enrollments in the clinical trials for JANX007 and JANX008, with first patient dosing in collaboration with Merck generating a $10 million milestone payment. Despite a strong cash position of $996 million, the company reported a net loss of $33.9 million for the quarter, reflecting increased research and development costs compared to the previous year.
Read more →JANXJanux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights • Phase 1b expansion study initiated with JANX007 in taxane-na ve mCRPC patients • Updated JANX007 data from Phase 1a
Janux Therapeutics reported its first-quarter 2025 financial results, highlighting the initiation of a Phase 1b expansion study for its drug JANX007 in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC). Updated results from the Phase 1a trial showed promising median progression-free survival, with median rates slightly improving. The company maintains a robust financial position, with over $1 billion in cash and equivalents, and plans to present additional data later in the year.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights • Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC • Enrollment
Janux Therapeutics reported positive financial results and business highlights for Q4 and full year 2024. The company presented encouraging Phase 1 clinical trial data for its drug JANX007, showing significant prostate-specific antigen response rates and durable declines in mCRPC patients. With a strong cash position of $1.03 billion, Janux is positioned to advance its clinical development plans and upcoming R&D activities slated for 2025. Progress on clinical trials for both JANX007 and JANX008 is ongoing, with further data updates expected next year.
Read more →JANX▲ +49%on this news
Janux Therapeutics Announces Proposed Public Offering
Janux Therapeutics has announced a proposed public offering of $300 million in shares of its common stock, with an additional option for underwriters to purchase up to $45 million more. The company plans to use the proceeds to advance its clinical development programs. Janux's proprietary technology focuses on tumor-activated immunotherapies, which aim to treat various solid tumors while minimizing safety concerns. However, the offering's success hinges on market conditions and other factors.
Read more →JANX▼ -11.1%on this news· ran to +47% by day 3shared move
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC • Emerging JANX007 data demonstrated subs
Janux Therapeutics has selected doses for Phase 1b expansion trials of its JANX007 therapy, which has shown substantial clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC). In a Phase 1a trial, 100% of patients exhibited PSA50 declines, with a majority achieving deeper and durable responses. The safety profile of JANX007 appears favorable, primarily involving low-grade adverse events. As Janux moves forward into more advanced trials, they highlight a substantial unmet need for this patient population.
Read more →JANXJanux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights • Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors • Update o
Janux Therapeutics announced its third quarter 2024 financial results, highlighting ongoing enrollment in its clinical trials for the PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008). The company reported $658 million in cash and equivalents and a net loss of $28.1 million for the quarter, representing a significant increase compared to the previous year. Looking ahead, Janux anticipates updates on its JANX007 program by the end of the year, with further expansions planned for both clinical trials in the coming years.
Read more →JANXJanux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights • Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors • Update
Janux Therapeutics reported strong financial results for Q2 2024, showing solid cash reserves of $646.3 million and ongoing clinical trials for its cancer therapies JANX007 and JANX008. The company received a $7.5 million milestone payment from Merck, further underscoring its partnership strengths. Recent appointments to the board are viewed as strategic moves to bolster leadership. However, the announcement acknowledged potential risks associated with clinical trial outcomes and regulatory approvals.
Read more →JANX▲ +6.8%on this news
Janux Therapeutics Announces Updates to Board of Directors • The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate
Janux Therapeutics has appointed Eric Dobmeier and Natasha Hernday to its Board of Directors, enhancing its strategic capabilities in drug development. Dobmeier brings over 20 years of biopharmaceutical experience, having led a company through a significant acquisition. Hernday has a proven track record in securing high-value partnerships and business development. The company also announced the resignation of Jay Lichter and the appointment of Ronald Barrett as Chairperson, reflecting ongoing changes in leadership as Janux advances its clinical pipeline.
Read more →JANXJanux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights • Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer • Enrollment ongoing for EGFR-TRACTr (JANX008) in so
Janux Therapeutics has announced its financial results for the first quarter of 2024, revealing a cash balance of $651.8 million. The company is currently progressing with enrollment for two clinical trials, JANX007 and JANX008, targeting prostate cancer and solid tumors. As part of its business strategy, Janux anticipates further updates on clinical data in the latter half of 2024. The company reported a reduced net loss compared to the previous year, reflecting improved financial management.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights • Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr
Janux Therapeutics announced its financial results for Q4 and the full year of 2023, highlighting positive Phase 1 clinical trial data for its drugs JANX007 and JANX008. The company reported a year-end cash position of $344 million and raised approximately $320.2 million in a recent underwritten offering. Key program milestones include ongoing enrollment in Phase 1 trials, with an update on data for JANX007 expected in the second half of 2024. Despite a net loss of $58.3 million for the year, the firm remains optimistic about its potential to address cancer treatment needs.
Read more →JANX▲ +229.5%on this news
Janux Therapeutics Announces Proposed Public Offering of Common Stock
Janux Therapeutics has announced a proposed public offering of $175 million in common stock to support its clinical development and general corporate purposes. The offering is subject to market conditions, and the company expects to grant underwriters an option to purchase additional shares. Janux aims to use the proceeds to further its internal product pipeline targeting various cancers with its proprietary immunotherapy technology. The company's TRACTr and TRACIr platforms are currently focused on several therapeutic candidates in clinical development.
Read more →JANXJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors • Emerging JANX007 data illustrate a potentia
Janux Therapeutics has announced positive interim clinical data for its TRACTr candidates, JANX007 and JANX008, which are being investigated for metastatic castration-resistant prostate cancer and solid tumors, respectively. The data reveal promising efficacy and a favorable safety profile, with significant PSA50 declines observed in patients treated with JANX007. Additionally, JANX008 demonstrated a partial response in a patient with non-small cell lung cancer, reinforcing its potential. The company plans to continue dose escalation trials to further evaluate the treatments.
Read more →JANXJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights • Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer • Enrollment ongoing for EGFR-TRACTr (JANX008) in so
Janux Therapeutics reported its financial results for the third quarter of 2023, highlighting ongoing enrollment in two Phase 1 clinical trials for its PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) programs. The company maintains a strong cash position of $349.7 million, projected to support operations through 2027. Financially, Janux reported a reduced net loss of $11.6 million compared to the previous year's quarter, reflecting improved operational efficiency. Future clinical updates are anticipated in 2024, signaling ongoing development and potential advancements in cancer therapies.
Read more →JANXJanux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer - Management team bolstered wit
Janux Therapeutics has reported encouraging interim Phase 1 clinical trial results for its PSMA-TRACTr JANX007 in prostate cancer. The company has strengthened its financial outlook with an additional $60 million funding and enhanced its management team. Despite a net loss of $17.5 million for the second quarter of 2023, Janux remains optimistic about advancing its pipeline of cancer therapies. The firm continues to explore its TRACTr and TRACIr technologies for cancer treatment.
Read more →JANXJanux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Janux Therapeutics announced a $60 million underwritten offering of common stock and pre-funded warrants to enhance its capital for the development of its immunotherapy pipeline. The offering includes 4,153,717 shares priced at $12.46 each, along with pre-funded warrants at $12.459 each. The offering is expected to close around July 19, 2023, but is subject to customary closing conditions. BofA Securities, Inc. is acting as the sole book-runner for the offering.
Read more →JANXJanux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs Multiple patients treated with PSMA-TRACTr JANX007 have achieved meanin
Janux Therapeutics announced positive interim clinical data for its PSMA-TRACTr JANX007 in a Phase 1a trial for metastatic castration-resistant prostate cancer. The data indicated significant PSA reductions in several patients, coupled with low-grade and transient cytokine release syndrome. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities observed. The company expressed confidence in the ongoing development of JANX007 and outlined additional clinical programs in its pipeline.
Read more →JANXJanux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights -First patient dosed with EGFR-TRACTr (JANX008) in first-in-human Phase 1 clinical trial in patients with solid tumors- -Interim cli
Janux Therapeutics reported its financial results for Q1 2023, highlighting key advancements in its clinical trials. Most notably, the company dosed its first patient with the EGFR-TRACTr (JANX008) in a Phase 1 trial for solid tumors. The financials reflected a net loss of $17.5 million, up from $13.4 million during the same period in the previous year. With $316.9 million in cash reserves, Janux continues to prioritize its TRACTr and TRACIr platforms for future development.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigationa
Janux Therapeutics reported its financial results for Q4 and the full year 2022, highlighting a robust cash position of $327 million. The company received FDA clearance for its EGFR-TRACTr IND application and is actively enrolling patients in the Phase 1 trial for its PSMA-TRACTr candidate. Upcoming milestones include an expected interim update from the JANX007 trial in the second half of 2023. Janux's leadership emphasized its commitment to advancing its immunotherapy pipeline amidst recent industry challenges.
Read more →JANX▲ +8.3%on this news
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights -First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update fro
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights -First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -IND appl
Read more →JANXJanux Therapeutics Appoints Winston Kung to Board of Directors
Janux Therapeutics Appoints Winston Kung to Board of Directors SAN DIEGO, September 22, 2022 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Acti
Read more →JANX▼ -9.7%on this news
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights -IND application cleared for lead product candidate JANX007 (PSMA-TRACTr)- -Phase 1 clinical trial evaluating JANX007 for metastati
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights -IND application cleared for lead product candidate JANX007 (PSMA-TRACTr)- -Phase 1 clinical trial evaluating JANX007 for metastatic castration-resistant prostate cancer remains on-track to
Read more →JANX▲ +5%on this news
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights -IND application recently submitted for PSMA-TRACTr (JANX007)- -Company remains on-track to submit IND application for EGFR-TRACTr (
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights -IND application recently submitted for PSMA-TRACTr (JANX007)- -Company remains on-track to submit IND application for EGFR-TRACTr (JANX008) in 2H 2022- -Merck nominates second target as pa
Read more →JANXJanux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results -Company remains on-track to submit IND filings for two programs in 2022- -Company nominated its first TRACIr de
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results -Company remains on-track to submit IND filings for two programs in 2022- -Company nominated its first TRACIr development candidate, a PD-L1 x CD28 costimulatory bispecif
Read more →JANX▼ -6.9%on this news
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results -Company remains on-track to submit IND filings for two programs in 2022- -Board of Directors strengthened with key appointments- -$
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results -Company remains on-track to submit IND filings for two programs in 2022- -Board of Directors strengthened with key appointments- -$387.5 million in cash and cash equivalents and short-term
Read more →JANXJanux Therapeutics Reports Second Quarter 2021 Financial Results -Successful $222.9 million IPO in June brings total funds raised in the quarter to $347.9 million- -Company on-track to submit IND filings for multiple pro
Janux Therapeutics Reports Second Quarter 2021 Financial Results -Successful $222.9 million IPO in June brings total funds raised in the quarter to $347.9 million- -Company on-track to submit IND filings for multiple programs in 2022- -Management team strengthened with key app
Read more →JANXJanux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares La Jolla, CA
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares La Jolla, CA, June 15, 2021 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immun
Read more →Competitive Position
How JANX ranks across every disease it competes inCompetitive Position is a premium feature
See how JANX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial